英矽智能称AI将药物候选开发压缩至约一年，Bora潜在25亿美元合作已提前公布

Hong Kong-listed Insilico Medicine (3696.HK) has cut drug development timelines to about one year by ​combining AI with its China research ecosystem, its CEO said, giving it an edge over traditional Western pharmaceutical giants.

Its strategy ‌highlights how China's growing role in global drug research, coupled with advances in AI, could further challenge established drugmakers, as the industry races to cut development costs and bring medicines to market faster.

"It usually takes about 4.5 years to get to a drug developmental candidate using the traditional approach. But if a pharma company has a research lab ​in China ... they cut two years of time," Insilico CEO Alex Zhavoronkov told Reuters in an interview at its Shanghai R&D ​facility.

"When you combine frontier AI that is proven to work experimentally with the power of China, you can significantly ⁠accelerate that. Now our record is nine months to a developmental candidate, with a typical timeline of 13 months."

Once known primarily as a low-cost ​manufacturer of generic drug ingredients, China has rapidly evolved into a major global hub for developing next-generation medicines, helped by lower research costs and streamlined ​regulation.

In China, clinical development could be conducted three times faster and at roughly half the cost of Europe, a senior Pfizer (PFE.N) executive said last month. The U.S. has taken actions to speed up drug research to counter the Chinese biotech industry.

It typically takes 5-7 years to bring a drug development candidate to the market in China, compared to ​at least 8-10 years in the West.

"We now compete with Chinese pharmaceutical companies on timelines, and with traditional biotechnology companies in the West on ​novelty," said Zhavoronkov, whose Shanghai R&D lab has automated the biological sampling and screening process.

FOCUS ON MARKETS OUTSIDE CHINA

Insilico has partnered with major drugmakers such as Eli Lilly (LLY.N) and ‌Japan's Takeda (4502.T) ⁠on research and development. Last week, it announced a cooperation with Taiwan's Bora Pharmaceuticals (6472.TW) potentially valued at over $2.5 billion. But no experimental medicines it is developing are yet approved for sale.

The U.S.-founded startup was an early pioneer in applying generative AI to drug discovery, and its first AI-designed drug, Rentosertib, has advanced to Phase II clinical trials.

AI has helped the company generate 31 developmental candidates over the past six years, a key milestone on the path ​to preclinical testing and human trials.

The ​firm conducts frontier AI research ⁠in Montreal and Abu Dhabi, while experimental drug validation and scaling take place in China, Zhavoronkov said. It customises and conducts post-training for foundational AI models using proprietary benchmarks tailored for drug discovery.

Despite its China presence, more ​than 90% of Insilico's revenue comes from Western pharmaceutical companies, Zhavoronkov said, declining to disclose a China revenue ​breakdown. China's lower ⁠national insurance reimbursement rates for ultra-novel drugs make Western licensing deals far more lucrative for pharma firms.

He added the company avoids selling most of its software in China because of potential geopolitical issues, although it plans to expand its Shanghai research footprint in future.

Zhavoronkov, however, warned of how wider AI adoption could disrupt ⁠workforce and ​resource deployment across the biotech industry, as companies automate more research and software functions.

"In my ​organization with 400 people, I can probably displace 40% easily on the software side," he said, adding that laboratory bench scientists and software engineers at his firm are being retrained ​to manage AI benchmarks and robotics.